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Introduction 
Small cell lung cancer (SCLC) constitutes about 15-20
per cent of all lung cancer cases and is strongly corre-
lated with cigarette smoking [26]. It is characterized
by a high growth rate, early and widely spread metas-
tases, especially to lymph nodes, bone marrow and
brain [1]. Despite initial sensitivity to chemotherapy in
most cases, SCLC almost inevitably relapses, more
than 95 % of patients eventually die of  cancer [9].
More than 90% of SCLC cases are the typical SCLC.
The remaining are recognized as combined SCLC with
non-small cell lung cancer (NSCLC) component [20].
The treatment of SCLC, unlike NSCLC, usually
involves chemo- and radiotherapy, surgical resection is
rarely performed, mostly for patients with stage I lim-
ited disease [20]. For this reason, access to SCLC
tumor specimens is limited for ex vivo experiments.
Thus, establishing SCLC cell lines is essential for fur-
ther studies on tumor biology and pathology. 
In this paper, we describe the establishing and char-
acterization of a new SCLC cell line derived from 
a combined small cell lung cancer with a non small
cell component (SCLC/NSCLC) bioptate obtained
from a supraclavicular lymph node metastasis.
Materials and methods
Patient history and biopsy specimen. A 54-year-old, smoking
woman was admitted to the hospital due to enlarged opacity in
the X-ray film of the upper mediastinum, reccuring fevers, cough
and exertional dyspnoea. The patient gave a several months his-
tory of  cough and pyrexia prior to hospitalization. Physical
examination revealed palpable 3 cm supraclavicular tumor. CT
scan revealed 10cm mass in the right mediastinum, fusing with
two others. On bronchoscopy micronodular lesions of the right
brochi were present. Serum LDH concentration was markedly
increased. In order to establish a diagnosis a fine-needle aspira-
tion biopsy (FNAB) of supraclavicular lymph node was taken.
The aspirate was split. One part was fixed in ethanol for cytolog-
ical examintation and the other was placed in sterile physiologi-
cal saline for culturing. The examination of FNAB smear in the
light microscopy revealed cancer cells with the features of SCLC
and NSCLC and finally combined type of SCLC was diagnosed.
After completion of diagnosis the patient was discharged from
the hospital in a good general condition and recommended for
treatment in oncology center.
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Cell culture. The obtained aspirate from a fine-needle biopsy of
supraclavicular lymph node was placed in sterile physiological
saline and taken to a laboratory. Then it was placed in a 25 cm3 cul-
ture flask in RPMI-1640 (Gibco) medium supplemented with 10%
new-born calf serum (NCS) (Biochrom)  and standard antibiotics,
penicillin and streptomycin and kept at 37°C in a humidified
atmosphere in CO2 incubator (5% CO2). The culture medium was
changed twice a week. After a month of culturing (10 passages) the
cells were banked RPMI-1640 with 20% NCS and 10% DMSO
and stored in liquid nitrogen. A few months later the cells were
thawed out and re-cultured. After 30 passages, cells were consid-
ered an established cell line and then characterized.   
Morphological studies. The tumor cells used to initiate the cell
line were reviewed. For cytological examination of the cell line,
cells suspension was  centrifuged, and cells smear was done, fixed
with Cytofix (Samko, Poland) and stained with Hematoxylin-
Eosin(H-E). The growth pattern of the established line was
described under a phase-contrast microscope. 
Growth studies. Kinetics in liquid culture was assayed in RPMI-
1640 medium with 10% heat-inactivated normal calf serum (NCS)
supplemented with 1% penicillin/streptomycin in 25-mm Petri
dishes. Cells were placed into a dish, pipetted vigorously and
counted in Burker hemocytometer. Cell counting was performed
after 24h, 48h, 72h and 96h. 
Colony forming efficiency. The colony-forming efficiency was
determined by suspending single cells in a semisolid methylcellu-
lose medium (MethoCult H4230, StemCell Technologies). 5x103
cells per 25 mm Petri dish was used and colonies were counted
after 7 days using phase-contrast microscope.
Flow cytometry. Cell surface staining was performed as described [17].
Briefly, 30 µl of cells suspension was labeled with 7 µl of the monoclonal
antibody of interest for 30 min. at room temperature and then washed with
1 ml of 2% serum in PBS and re-suspended in 300 µl of 0.5% formalde-
hyde in PBS. Then, the probes were acquired to FACS Calibur flow
cytometer (Becton-Dickinson, San Jose, California). The cells were col-
lected by CELLQuest software. For the intracellular staining, cells were
fixed in 4% formaldehyde for 20 min., washed in PBS, stored in 70%
ethanol and permeabilized before further treatment by 0.1% NP-40 in PBS
for 30 min. at room temp. After the permeabilization, the labeling was per-
formed as for surface antigens.
The following monoclonal antibodies (mAb) were used: anti-
CD56 (NCAM) FITC, anti-Fas(CD95) PE-Cy5 (BD Bioscience,
San Jose), anti-Cytokeratin 19 (CK19) (Santa Cruz Biotechnolo-
gy), MOC-1 (a generous gift from dr de Leji), anti-Bcl2 FITC,
anti-EBV(anti LMP-1),anti-p53 FITC, (Dako Cytomation), anti-
HLA-ABC PE-Cy5, anti-CXCR4 PE, anti-CD210 PE. Fluores-
cently unconjungated mAbs were stained with Zenon Alexa Fluor
488 labeling kit (Molecular Probes), as previously desribed [6].




Cytological examination of the H+E stained smear of
FNAB obtained from supraclavicular lymph node
revealed mixed pattern. There was domination (about
80%) of small cells with scant cytoplasm, ill-defined
cell borders, finely granular nuclear chromatin, and
absent or inconspicuous nucleoli. Nuclear smearing
was visible. Apart from SCLC cells we found admix-
ture of the cells with typical features of non- small cell
type. There were anaplastic cells with well preserved
cytoplasm however, without cell borders and with
marked nuclear boarding and conspicuous nucleoli.
The aggregates  of these cells suggested adenocarcino-
ma. Interestingly, when the cultured cells underwent
cytological examination after 30 passages, it occured
that only small cell component of the starting material
was present. The new STP54 SCLC cell line grew as
relatively tightly packed floating aggregates, amor-
phous and irregular in shape. Some cells formed char-
acteristic chains (Fig.1). This cell line fits type 2
growth pattern according to  Carney et al. [7]. Under
high magnification numerous cytoplasmic neurosecre-
tory dense core granules could be seen (Fig.1) 
Growth kinetics and colony forming assay
The cells were passaged 30 times before considered an
established cell line, named STP54. However, this cell
line has been cultured for even more than 60 passages.
Growth kinetics was assessed by cell counting. The
results were put on a chart which was used to calculate
Population Doubling Time, by the 'best fit' method.
The graph was described by y= -141.85+361.4x-
223.47x2+60.879x3. The calculated PDT was 68 h. 




The expression of selected markers, analyzed by flow
cytometry is summarized in Table 1. and Fig. 2. STP54
expressed high level of Cytokeratin19, which is 
a marker of lung epithelial cells and lung cancers.
Also, Neural Cell Adhesion Molecule was detected by
MOC-1 antibody in most of the cells. Both of these
molecules are characteristic for the classic SCLC.
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Table 1. Expression of selected markers in the new STP54 cell
line. 
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Fig. 1. STP54 cells form floating aggregates
(a). Numerous intracellular granules can be
seen, especially under the stronger maginifi-
cation (b). 
Fig. 2. Immunophenotyping  of the new STP54
cell line by flow cytometry analysis. Cells positive
for the selected markers are gated in the cytograms
(a-d). Histograms show the fluorescence intensity
of  cells labeled with specific mAbs in red and
purple and controls in green. (a) Cytokeratin 19,
(b) NCAM, (c) HLA-ABC, (d) Fas, (e) LMP-1, 
(f) IL-10R, (g) CXCR4, (h) Bcl-2.
Expression of HLA-ABC was low.  Infection by
Epstein-Barr Virus was found by the expression of
Latent Membrane Protein 1. P53 tumor suppressor
protein was not detected by immunocytochemistry,
while low expression of Bcl-2 oncogene was noticed.
Additionally, almost all cells were positive for the
chemokine CXCR4 receptor and a significant subpop-
ulation expressed the Fas receptor and for interleukin-
10 receptor (CD210).  The composition of the cell line
population suggests the heterogeneity of cells.
Discussion
Combined small cell lung cancer with non-small cell
component is a rarely occurring lung tumor which is
thought to be characterized by more aggressive clin-
ico-pathologic behaviour than histologically pure
tumors [22]. Here, we present a cell line derived
from a 54-year-old woman who was diagnosed with
SCLC/NSCLC (stage IV, extensive disease). At the
admission the patient  presented typical symptoms,
and the radiological pattern of SCLC. The diagnosis
was based on the cytological examination of a fine-
needle biopsy-derived specimen. Several studies
have reported successful establishment of SCLC cell
lines in a chemically defined medium such as HITES
or ACL-3 with a high efficiency (up to 70%) [7,21].
However, other studies reveal that cell lines derived
in such conditions are unable to grow for a long peri-
ods of time, indicating that the serum supplementa-
tion is required for establishing permanent cell lines
[25]. Unfortunately, under such conditions the effi-
ciency of establishing cell lines reaches maximally
10 per cent [2,12]. We attempted successfully to
establish cell line in a serum-supplemented growth
medium and after 30 passages we have regarded the
cells as an established cell line. Up to the present, the
cells have been cultured for more than 7 months. Of
interest, repeated cytological examination of the cul-
tured cells revealed the presence of small cell lung
cancer only. Morphologically, the cells formed float-
ing clusters, a typical growth pattern of SCLC in the
liquid milieu. The population doubling time of this
line reached 68 hours and is within the range of other
reported SCLC cell lines [7]. Also, the colony form-
ing efficiency, which is 0.72 per cent, is similar to
those described previously [14].
Analysis by immunofluorescence staining using
monoclonal antibody to CK19 showed positive stain-
ing for human cytokeratin, verifying the epithelial
origin of this tumor [4]. MOC-1 also binds to the
NCAM molecule confirming the SCLC diagnosis
[5,11].  Reduced proportion of Fas receptor expres-
sion cells is known to exist in some cancers, includ-
ing lung cancers. The low Fas expression is probably
one of the main strategies developed by tumor cells
to avoid apoptosis induced by activated T cells pro-
ducing FasL [15].  Another molecule that is extreme-
ly important in the  immunosurveillance mechanisms
is the HLA-ABC (major histocompatibility complex
class I). HLA-ABC enables recognition of mutated
and virus-infected cells by the immune system. It was
shown that low expression of this molecule on cancer
cells is correlated with the poor prognosis due to
numerous metastases and clinical aggressiveness
[10,13]. We found very poor expression of HLA-
ABC on the STP54 cell line, which might be respon-
sible for fast  clinical progress and metastases found
in the patient. 
Aside from the "classic" antigens, we have also
checked the expression of CXCR4, a chemokine
receptor for the Stromal-Derived Factor-1 (SDF-1).
The STP54 cell line shows a high positive staining
for CXCR4, what confirmes the presence of this
receptor in SCLC [6]. The CXCR4/SDF-1 axis is
often thought to be a key mechanism responsible for
cancer metastasis [18]. This notion might be right
also in this case, as the cells were aspirated from 
a metastatic site localized in a lymph node. Another
receptor that was detected on a subpopulation of the
STP54 cells was CD210, a receptor for interleukin
10. The role of this cytokine in SCLC has not been
described, however there are some contradictory
papers of its impact on NSCLC [22,23]. Latent
Membrane Protein-1 (LMP-1), a molecule character-
istic for Epstein-Barr Virus infection was found on
the STP54 cells. EBV is often regarded as an onco-
genic factor, but the significance of LMP-1 in lung
cancers is uncertain and requires further investiga-
tion [8].
Numerous mutations in the p53 gene are known
in SCLC. Introduction of the wilde-type p53 cDNA
into SCLC led to growth inhibition and chemosensi-
tivity [24]. These observations, together with the
absence of p53 by immunocytochemistry in our tests
in the STP54 cells, might suggest  chemoresistance.
On the other hand, Bcl-2, another factor known to be
responsible for chemoresistance in SCLC [19,27],
was expressed in low proportion of our new cell line.
Altogether, those facts suggest the existence of sev-
eral different ways of chemoresistance developed by
SCLC.
In conclusion, we have successfully established a
new small cell lung cancer cell line, which we named
STP54. We have characterized it by the growth prop-
erties, morphology, immunocytochemical expression
of selected antigens and sensitivity to cisplatin. This
cell line will be used in the future to study the tumor
biology and to develop new therapeutical strategies.
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